Introduction {#section1-1534735418786801}
============

Breast cancer remains the second leading cause of cancer-related death among women. Hormonal therapy, a standard breast cancer adjuvant therapy, is one of the most widely used treatments for breast cancer patients and effectively reduces death and recurrence from breast cancer. Hormone treatments are effective against many types of breast cancer, but are, nevertheless, accompanied by side effects, including vasomotor syndrome, nausea, vomiting, fatigue, pain, hot flashes, and psychological stress.^[@bibr1-1534735418786801]^ These side effects present major hurdles to increasing the effectiveness of cancer treatment and can adversely affect quality of life, compliance with treatment, and overall survival. Important aspects of breast cancer therapy include relieving cancer-related pain,^[@bibr2-1534735418786801],[@bibr3-1534735418786801]^ fatigue,^[@bibr4-1534735418786801]^ and hot flashes^[@bibr5-1534735418786801]^ and improving the quality of life.^[@bibr6-1534735418786801],[@bibr7-1534735418786801]^

More than 11.2% of patients have used acupuncture as complementary and alternative medicine (CAM) in breast cancer treatment.^[@bibr8-1534735418786801]^ Acupuncture use among breast cancer patients in the United States is currently as high as 16% to 63%.^[@bibr9-1534735418786801],[@bibr10-1534735418786801]^ An increasing number of studies indicate that acupuncture can be used in treatment-related symptom control^[@bibr11-1534735418786801]^ and the alleviation of side effects caused by hormone treatment.^[@bibr7-1534735418786801],[@bibr12-1534735418786801]^ Acupuncture plays an important role in improving the overall quality of life of breast cancer patients.^[@bibr13-1534735418786801]^

The clinical application of needle therapy in ancient China is one of the oldest of the healing arts; this ancient form of treatment is gaining popularity as part of the contemporary CAM therapy movement today. Most literature has reported that acupuncture is a potentially beneficial, gentle treatment for cancer survivors, and research on acupuncture in breast cancer populations continues to attract growing attention, supplemented and supported by conservative optimism.^[@bibr14-1534735418786801]^ However, other studies reported no beneficial effect.^[@bibr15-1534735418786801][@bibr16-1534735418786801][@bibr17-1534735418786801]-[@bibr18-1534735418786801]^ The aim of this meta-analysis, therefore, was to assess the efficacy of acupuncture for treatment-related side effects of hormone therapy and the quality of life of patients with breast cancer.

Methods {#section2-1534735418786801}
=======

Search Strategy and Selection Criteria {#section3-1534735418786801}
--------------------------------------

A search was performed for randomized controlled trials (RCTs) studying the clinical benefits of acupuncture for the reduction of hormone therapy--related side effects in breast cancer patients. Only English-language published literature was searched; no publication date or status restrictions were imposed. We included women participants if they were (1) aged 18 years or older, (2) had a history of breast cancer, and (3) received active breast cancer treatments and/or were administered hormone therapy. Patients with prior acupuncture use for aromatase inhibitor (AI)-induced joint symptoms or acupuncture within 6 months before enrollment were excluded. All types, doses, and regimens of acupuncture and electroacupuncture versus a placebo or control group were included. Primary outcome measures were hormone therapy--related side effects; a secondary outcome measure was physical well-being.

Data Sources and Searches {#section4-1534735418786801}
-------------------------

Studies were identified by searching databases, scanning reference lists, and consultation with breast cancer and traditional Chinese medicine (TCM) experts. The databases included PubMed (1966 to November 2017), EMBASE (1974 to November 2017), the Cochrane Library (issue 4 through 2017), and the Web of Science (1974 to November 2017) using the following terms: ("breast neoplasms"\[MeSH Terms\] OR "breast neoplasm"\[Title/Abstract\] OR "breast cancer"\[Title/Abstract\] OR "breast tumor"\[Title/Abstract\] OR "breast neoplasms"\[Title/Abstract\] OR "breast cancers"\[Title/Abstract\] OR "breast tumors"\[Title/Abstract\]) AND "electro-acupuncture" \[MeSH Terms\] OR "electro-acupuncture"\[Title/Abstract\] OR "Electroacupuncture" \[MeSH Terms\] OR "Electroacupuncture"\[Title/Abstract\] OR ("Acupuncture"\[MeSH Terms\] OR "Acupuncture"\[Title/Abstract\]) AND (random\* OR "Clinical Trials as Topic"\[Mesh\] OR "Clinical Trial" \[Publication Type\]). Reference lists were reviewed to identify additional studies, and the final bibliography was distributed to experts to identify missing studies.

Data Abstraction and Assessment of Bias Risk {#section5-1534735418786801}
--------------------------------------------

This systematic review was performed according to the Cochrane Handbook version 5.2. Three reviewers (Yuanqing Pan, Xiue Shi, and Haiqian Liang) independently selected studies by screening titles, abstracts, and the included studies after scanning the full texts. The following information was extracted: (1) trial participant characteristics (including age, stage, current treatment, duration, and outcome measures) and (2) type of intervention (including type, dose, duration, and frequency of acupuncture) versus the placebo/control group. Further information was obtained from study authors when needed. Risk of bias was assessed according to the Cochrane Collaboration Handbook^[@bibr19-1534735418786801]^ and evaluated sequence generation, allocation concealment, blinding of the study participants and investigators, whether incomplete outcome data were addressed, selective outcome reporting, and other sources of bias. Three authors independently performed data extraction and quality assessment. All disagreements during study selection, data extraction, and quality assessment were resolved by consensus or discussions with a third author.

Data Analysis {#section6-1534735418786801}
-------------

For continuous outcomes, the standardized mean difference or mean difference and 95% CI were calculated. Binary outcomes were pooled by using an odds ratio and 95% CI. A subgroup analysis was conducted according to the end point measurement methods and evaluated subjects. The meta-analysis was performed with Stata software (version 10.0, Stata Corp, College Station, TX).^[@bibr20-1534735418786801]^

Results {#section7-1534735418786801}
=======

Description of Studies {#section8-1534735418786801}
----------------------

A total of 245 studies were identified by searching the PubMed, EMBASE, Web of Science, Ovid MEDLINE, and Cochrane Library databases; 46 duplicates and 182 studies did not meet the inclusion criteria and were subsequently excluded. The baselines of the trials were comparable. The selection process is shown in [Figure 1](#fig1-1534735418786801){ref-type="fig"}. A total of 17 studies were included.^[@bibr2-1534735418786801][@bibr3-1534735418786801][@bibr4-1534735418786801][@bibr5-1534735418786801][@bibr6-1534735418786801]-[@bibr7-1534735418786801],[@bibr15-1534735418786801][@bibr16-1534735418786801][@bibr17-1534735418786801]-[@bibr18-1534735418786801],[@bibr21-1534735418786801][@bibr22-1534735418786801][@bibr23-1534735418786801][@bibr24-1534735418786801][@bibr25-1534735418786801][@bibr26-1534735418786801]-[@bibr27-1534735418786801]^ [Tables 1](#table1-1534735418786801){ref-type="table"} and [2](#table2-1534735418786801){ref-type="table"} summarize the characteristics of the included studies.

![Flowchart of the results of the literature search.](10.1177_1534735418786801-fig1){#fig1-1534735418786801}

###### 

Characteristics of the Included Studies.

![](10.1177_1534735418786801-table1)

  Authors/Year/Country                                                  No. of Patients (Acupuncture Group/Control Group)   Mean Age of Acupuncture Group (years)                                                                                   Mean Age of Control Group (years)   Status of Cancer   Current Treatment                                                                       Hormone Therapy                                                                                                         Duration   Outcome Measures/Results
  --------------------------------------------------------------------- --------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- ----------------------------------- ------------------ --------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- ---------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Bao et al, 2013,^[@bibr2-1534735418786801]^ United States             23/24                                               61 (44-82)                                                                                                              61 (45-85)                          0-III              Hormone replacement therapy, letrozole, anastrozole, exemestane                         Letrozole and/or anastrozole, and/or exemestane, ≥1 month                                                               8 Weeks    Significant improvements in HAQ-DI (*P* \< .03), pain (VAS), significant reduction of IL-17 (*P* \< .009), no significant modulation was seen in estradiol, β-endorphin, or other proinflammatory cytokine (*P* \> .05)
  Crew et al, 2007,^[@bibr3-1534735418786801]^ United States            9/9                                                 47 ± 1.1 Of 11 patients (52%) who reported taking analgesics (acetaminophen, NSAIDs, or COX-2 inhibitors) at baseline   43 ± 1.5                            II-III             Medicated with tamoxifen, postoperative radiation and chemotherapy                      Letrozole and/or anastrozole, and/or exemestane, 6 months                                                               6 Weeks    Significant improvements in anxiety (HADS-A; *P* \< .001), depression (HADS-D; *P* \< .001), and PSS in true acupuncture group (*P* \< .001)
  Crew et al, 2010,^[@bibr4-1534735418786801]^ United States            20/18                                               58 (44-77)                                                                                                              57 (37-77)                          I-III              Medicated with tamoxifen, chemotherapy, and radiotherapy                                Letrozole and/or anastrozole, and/or exemestane, 6 months                                                               6 Weeks    Significant improvement in pain and physical well-being (BPI, *P* \< .01; WOMAC, *P* \< .01), significant improvement in quality of life (FACT-B and BPI-SF; *P* \< .01) in true acupuncture group
  Deng et al, 2007,^[@bibr15-1534735418786801]^ United States           42/30                                               53.5                                                                                                                    54                                  Unclear            Medicated with tamoxifen, postoperative radiation and chemotherapy, SSRIs               Tamoxifen and/or aromatase inhibitors, within 3 weeks                                                                   4 Weeks    No significant improvement in hot flashes/24 in true acupuncture group (*P* \> .05)
  Nedstrand et al, 2005,^[@bibr27-1534735418786801]^ Sweden             19/19                                               53                                                                                                                      Unclear                             Unclear            Medicated with tamoxifen, postoperative chemotherapy and radiotherapy                   Tamoxifen treatments mentioned, no details                                                                              6 Months   Significant reduction in hot flushes (*P* \< .0001) in both groups, significant reduction in KI (*P* \< .0001) in both groups
  Frisk et al, 2008,^[@bibr23-1534735418786801]^ Sweden                 36                                                  56.5                                                                                                                    53.4                                I - III            Medicated with Tamoxifen, postoperative radiation and chemotherapy                      \>2 Years sequential estrogen/progestagen combination, \>2 years after menopause, given combined estrogen/progestagen   6 months   Significant reduction in hot flushes (*P* \< .001) in the electroacupuncture group, significant reduction in KI in both groups (*P* \< .05)
  Hervik and Mjåland, 2009,^[@bibr21-1534735418786801]^ Norway          30/29                                               53.6 ± 6.4                                                                                                              52.3 ± 6.9                          Unclear            Postoperative radiation and chemotherapy                                                Tamoxifen for at least 3 months, mentioned, no details                                                                  6 Weeks    Significant reduction in hot flashes (*P* \< .001) in both groups; significant reduction in KI in true acupuncture group (*P* \< .0001) and small reduction (*P* = .06) in the sham acupuncture group
  Hervik and Mjåland, 2014,^[@bibr22-1534735418786801]^ Norway          43/45                                               52.5                                                                                                                    50.2                                Unclear            Postoperative, medicated with tamoxifen                                                 Tamoxifen for 3 months                                                                                                  10 Weeks   Significant reduction in KI
  Johnston et al, 2011,^[@bibr5-1534735418786801]^ United States        5/7                                                 55 ± 6.40                                                                                                               53 ± 7.2                            Unclear            Medicated with hormone replacement therapy, postoperative radiation, and chemotherapy   Hormone replacement therapy mentioned, no details                                                                       8 Weeks    Significant decline in fatigue (BFI; *P* \< .10) in true acupuncture group, no significant improvement in cognitive dysfunction (FACT-B; *P* \> .05) in true acupuncture group
  Liljegren et al, 2012,^[@bibr6-1534735418786801]^ Sweden              38/36                                               58 ± 6.8                                                                                                                58 ± 9.3                            I                  Medicated with tamoxifen, and chemotherapy                                              Tamoxifen treatments mentioned, at least 2 months                                                                       6 Weeks    Significant reduction in hot flushes (*P* \< .001), significant improvement in physical well-being (WOMAC; *P* \< .01)
  Mao et al, 2014,^[@bibr18-1534735418786801]^ United States (I)        19/21                                               57.5 ± 10.1                                                                                                             60.9 ± 6.5                          I-III              Postoperative, medicated with tamoxifen, and chemotherapy                               Anastrozole, letrozole, exemestane                                                                                      12 Weeks   Significant improvements in pain (BPI; *P* \< .00), stiffness (WOMAC; *P* \< .0.00); no significant improvement on upper PPT (*P* \> .05)
  Mao et al, 2014,^[@bibr24-1534735418786801]^ United States (II)       19/21                                               57.5 ± 10.1                                                                                                             60.9 ± 6.5                          I-III              Hormone therapy                                                                         Anastrozole, letrozole, exemestane                                                                                      12 Weeks   Significant improvements in fatigue (BFI; *P* \< .0095), anxiety (HADS; *P* \< .044), depression (HADS; *P* \< .015), and sleep disturbance (PSQI; *P* \< .058)
  Mao et al, 2015,^[@bibr25-1534735418786801]^ United States            30/32                                               52.9 ± (8.6)                                                                                                            52 ± (8.9)                          I-III              Hormone replacement therapy                                                             Tamoxifen, aromatase inhibitor mentioned, no details                                                                    8 Weeks    Significant reduction in hot flash composite score (HFCS; *P* \< .001)
  Molassiotis et al, 2013,^[@bibr16-1534735418786801]^ United Kingdom   56/49                                               46                                                                                                                      53                                  I-IIIa             Medicated with tamoxifen, postoperative radiation and chemotherapy                      Hormone treatments mentioned, no details                                                                                10 Weeks   No significant improvement in fatigue (MFI; *P* \> .05), emotional well-being (HADS; *P* \> .05), and quality of life (FACT-B; *P* \> .05)
  Nedstrand et al, 2006,^[@bibr7-1534735418786801]^ Sweden              17/14                                               30-64(53)                                                                                                               Unclear                             Unclear            Postoperative radiation and chemotherapy                                                Tamoxifen treatments mentioned, at least 12 weeks                                                                       6 months   Significant reduction in hot flashes (*P* \< .001), significant reduction in KI (*P* \< .0001), significant reduction in pain (VAS; *P* \< .0001) in both groups, significant improvement in psychological well-being (SCL; *P* \< .0001) in both groups, mood improved significantly (MS; *P* \< .0001) in the electroacupuncture group
  Smith et al, 2013,^[@bibr17-1534735418786801]^ Australia              10/10                                               55 ± 8.8                                                                                                                53 ± 12.5                           Unclear            Surgical treatment                                                                      Hormone treatments mentioned, no details                                                                                6 Weeks    No significant reduction in fatigue (BPI-SF; *P* \> .05), significant improvement in quality of life (MYCaW; *P* = .006)
  Yao et al, 2016,^[@bibr26-1534735418786801]^ Korea                    15/15                                               56.2 ± 5.82                                                                                                             55.8 ± 5.02                                            Chemotherapy, radiation therapy                                                         Not mentioned                                                                                                           6 Weeks    Lymphedema, significant improvement (*P* \< .0000); shoulder range of motion, significant improvement (*P* \< .0000); quality of life (QLQ-30), significant improvement (*P* \< .05)

Abbreviations: BFI, Brief Fatigue Inventory; BPI-SF, Brief Pain Inventory--Short Form; COX, cyclo-oxygenase; FACT-B, Functional Assessment of Cancer Therapy; HADS, Hospital Anxiety and Depression Scale; IL, interleukin; KI, Kupperman Index; MFI, Multidimensional Fatigue Inventory; MS, Mood Scale; MYCaW, Measure Yourself Concerns and Wellbeing questionnaire; NSAID, nonsteroidal anti-inflammatory drug; PPT, Physical Performance Test; PSQI, Pittsburgh Sleep Quality Index; PSS, Perceived Stress Scale; SCL, Symptom Checklist; SSRI, selective serotonin reuptake inhibitor; VAS, Visual Analogue Scale; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index; HAQ-DI, Health Assessment Questionnaire Disability Index; HADS-D, Hospital Anxiety and Depression Scale-Subscales of Depression; HADS-A, Hospital Anxiety and Depression Scale-Subscales of Anxiety; HFCS, Hot Flash Composite Score; QLQ, Quality of Life Questionnaire.

###### 

Characteristics of the Acupuncture Prescription.

![](10.1177_1534735418786801-table2)

  Author/Year                                                              Inclusion Criteria                                                      Instructor                                                                        Needles                                                                                                                                                                                                                                                                    Points                                                                                                                      Treatment Group                                                                                          Control Group                                                              Indications
  ------------------------------------------------------------------------ ----------------------------------------------------------------------- --------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------- --------------------------------------------------------------------------
  Bao et al, 2013,^[@bibr2-1534735418786801]^ United States                Clinical experience of acupuncturists                                   No mention                                                                        0.25 mm × 40 mm Sterilized and disposable acupuncture needles (DongBang AcuPrime, United Kingdom)                                                                                                                                                                          CV 4, CV6, CV12, bilateral LI 4, MH 6, GB 34, ST 36, KI 3, BL 65                                                            8 Weeks                                                                                                  Sham needles                                                               Qi (vital energy) deficiency
  Crew et al, 2007,^[@bibr3-1534735418786801]^ United States               STRICTA                                                                 Acupuncturists                                                                    Single-use, sterile, and disposable; full-body acupuncture needles were 25 mm or 40 mm and 34 gauge (G; Cloud & Dragon, Wujiang City Cloud & Dragon Medical Device Co, Ltd, China), and auricular needles were 15 mm and 38 G (Seirin, Seirin-America Inc, Weymouth, MA)   SJ5, GB41, GB34, LI 4, ST41, KD 3, LI15, SJ14, SI10, SJ4, LI5, SI5, SI3, LI3, DU-3, DU8, UB23, GB39 GB30, SP9, SP10, ST34   20-25 Minutes, twice weekly for 6 weeks                                                                  No treatment, observation at baseline                                      Pain and pain-related functional interference, gastrointestinal symptoms
  Crew et al, 2010,^[@bibr4-1534735418786801]^ United States               National Acupuncture Detoxification Association protocol                Acupuncturists                                                                    25 mm or 40 mm and 34 G (Cloud & Dragon Medical Device, Wujiang City, China), and auricular needles were 15 mm and 38 G (Seirin-America, Weymouth, MA)                                                                                                                     Standardized set of acupuncture points, no details                                                                          20-25 Minutes, twice weekly over 6 weeks                                                                 No treatment, observation at baseline                                      Pain, physical function, gastrointestinal symptoms, quality of life
  Deng et al, 2007,^[@bibr15-1534735418786801]^ United States              Referring to the published literature                                   Experienced physiotherapist                                                       Stainless steel filiform, needles sized 0.20 mm × 30 mm, manufactured by Seirin Corp (Shizuoka, Japan)                                                                                                                                                                     DU14, GB 20, BL 13, PC7, H6, K7, ST36                                                                                       20 Minutes, twice-weekly treatments for 4 weeks                                                          Sham needles                                                               Hot flushes
  Nedstrand et al, 2005,^[@bibr27-1534735418786801]^ Sweden                Referring to the published literature                                   Experienced physiotherapist                                                       12 Sterile, stainless steel acupuncture needles were inserted to a depth of 5-20 mm in defined points                                                                                                                                                                      BL15, BL23, BL32 bilaterally, HT7, SP6, SP9, LR 3, PC6, GV20                                                                30 Minutes twice a week for the first 2 weeks and once a week for 10 weeks                               Progressive relaxation programs                                            Hot flashes
  Frisk et al, 2008,^[@bibr23-1534735418786801]^ Sweden                    Referring to the published literature                                   Experienced physiotherapist                                                       2 Hz Electroacupuncture                                                                                                                                                                                                                                                    Unclear                                                                                                                     Electroacupuncture: 30 minutes twice a week for the first 2 weeks and once a week for another 8 weeks    No treatment, observation at baseline                                      Hot flashes
  Hervik and Mjåland, 2009,^[@bibr21-1534735418786801]^ Norway             Traditional Chinese medical textbooks                                   Physiotherapist with a 3-year certified training course from acupuncture school   Disposable 0.30-mm needles inserted between 0.5 and 3.0 cm                                                                                                                                                                                                                 LIV3, GB20, LU7, KI3, SP6, REN4, P7, LIV8                                                                                   30-Minute sessions twice weekly for the first 5 weeks                                                    Sham needles                                                               Hot flashes
  Hervik and Mjåland, 2014,^[@bibr22-1534735418786801]^ Norway             Mention                                                                 Unclear                                                                           Unclear                                                                                                                                                                                                                                                                    Unclear                                                                                                                     10 Weeks                                                                                                 Sham needles                                                               Hot flashes
  Johnston et al, 2011,^[@bibr5-1534735418786801]^ United States           Referring to the published literature                                   Acupuncturists                                                                    LEKON sterile disposable acupuncture needles of the following sizes: 34 G × 1.5 (0.22 mm × 40 mm diameter); 34 G × 1.0 (0.22 mm × 25 mm); 32G × 1.5 (0.25 mm × 40 mm); and 38G × 0.5 (0.18 mm × 13 mm)                                                                     Li4, SP6, ST36, KI3, P6, SP4, LU7, KI4, LIV3, GV20, H7, UB62, GB20, TE5, GB43, SI3, UB62, GB29, GB30, GB40                  50-Minute sessions for 8 weeks, frequency not mentioned                                                  Normal practice included pharmacological and nonpharmacological options    Fatigue, cognitive dysfunction
  Liljegren et al, 2012,^[@bibr6-1534735418786801]^ Sweden                 Referring to the published literature                                   Acupuncturists                                                                    8 Sterilized disposable needles sized 0.25 mm × 40 mm manufactured by DongBang acupuncture Inc were inserted to a depth of 5-20 mm                                                                                                                                         LI4, HT6, LR3, ST36 unilaterally and SP6 and KI7 bilaterally                                                                20 Minutes twice a week for 5 weeks                                                                      Sham needles                                                               Hot flushes, sweating, gastrointestinal symptoms
  Mao et al, 2014,^[@bibr18-1534735418786801]^ United States (I), Europe   Manualized protocol of traditional Chinese medicine theory              Nonphysician acupuncturists                                                       30 mm Or 40 mm and 0.25 G; Seirin-America Inc, Weymouth, MA                                                                                                                                                                                                                4 Points around the joint with the most pain                                                                                2-Hz electrostimulation of electroacupuncture: 30 minutes twice weekly for 8 weeks                       Waitlist control                                                           Pain, stiﬀness
  Mao et al, 2014,^[@bibr24-1534735418786801]^ United States (II)          Manualized protocol of traditional Chinese medicine theory              Nonphysician acupuncturists                                                       30 mm Or 40 mm and 0.25 G; Seirin-America Inc, Weymouth, MA                                                                                                                                                                                                                4 Points around the joint with the most pain                                                                                2-Hz electrostimulation of electroacupuncture: 30 minutes twice weekly for 8 weeks                       Waitlist control                                                           Depression, anxiety, fatigue
  Mao et al, 2015,^[@bibr25-1534735418786801]^ United States               Semistandardized treatment manual on the basis of existing literature   Nonphysician acupuncturists with 8 and 20 months experience                       Bilateral 2-Hz electroneedles, 30 or 40 mm and 0.25 mm G; Seirin-America, Weymouth, MA, left in position for 30 minutes                                                                                                                                                    Standard points depending on subjects' preferred positions and presenting symptoms (eg, fatigue and insomnia)               Twice per week for 2 weeks, once per week for next 6 more weeks, 8 weeks total                           Sham needles, selecting the same number of nonacupuncture trigger points   Hot flushes
  Molassiotis et al, 2013,^[@bibr16-1534735418786801]^ United Kingdom      Referring to the published literature; reporting in STRICTA             Experienced instructor                                                            Seirin with guide tubes for single use and their size 36 G/point 16-30 mm                                                                                                                                                                                                  ST36, SP6, LI4                                                                                                              20 Minutes per week for 6 weeks                                                                          Health education for self-acupuncture                                      Fatigue, emotional well-being
  Nedstrand et al, 2006,^[@bibr7-1534735418786801]^ Sweden                 Referring to the published literature                                   No mention                                                                        12 Sterile stainless steel acupuncture needles were inserted to a depth of 5-20 mm at defined point                                                                                                                                                                        Four needles in the lower back, BL 23 and 32 bilaterally                                                                    Electroacupuncture: 30 minutes twice a week for the first 2 weeks and once a week for another 10 weeks   Progressive relaxation programs                                            Climacteric symptoms, gastrointestinal symptoms, emotional well-being
  Smith et al, 2013,^[@bibr17-1534735418786801]^ Australia                 Referring to the published literature reporting in STRICTA              Acupuncturists                                                                    Single-use disposable stainless steel Vinco needles (0.25 mm × 40 mm and 0.22 mm × 25 mm)                                                                                                                                                                                  KI3, KI27, ST36, SP6, CV4, CV6                                                                                              20 Minutes for 6 weeks                                                                                   Health education for self-acupuncture                                      Pain
  Yao et al, 2016,^[@bibr26-1534735418786801]^ Korea                       Referring to the published literature                                   Professional medical practitioners                                                0.45 mm × 25 mm needles: Suzhou Medical Instruments, Suzhou City, China) thermoacupuncture                                                                                                                                                                                 Shousanli (LI.10), Quchi (LI.11), Binao (LI.14), Jianyu (LI.15), Waiguan (SJ.5), and Jianliao (SJ.14)                       30 Minutes on alternate days for 30 days                                                                 900 mg Diosmin tablets, orally 3 times daily for 30 days                   Lymphedema

Abbreviation: STRICTA, Revised Standards for Reporting Interventions in Clinical Trials of Acupuncture.

Study Characteristics {#section9-1534735418786801}
---------------------

A total of 13 RCTs were from Northern Europe^[@bibr6-1534735418786801],[@bibr7-1534735418786801],[@bibr9-1534735418786801],[@bibr16-1534735418786801],[@bibr22-1534735418786801],[@bibr23-1534735418786801],[@bibr27-1534735418786801]^ and North America,^[@bibr2-1534735418786801][@bibr3-1534735418786801][@bibr4-1534735418786801]-[@bibr5-1534735418786801],[@bibr16-1534735418786801],[@bibr18-1534735418786801],[@bibr24-1534735418786801],[@bibr25-1534735418786801]^ 1 was from Australia,^[@bibr17-1534735418786801]^ and 1 was from Korea.^[@bibr26-1534735418786801]^ Participant age across all RCTs ranged from 30 to 61 years; 1 RCT included patients with stage 0-III breast cancer, 1 included patients with stage II-III tumors,^[@bibr3-1534735418786801]^ and 7 RCTs included patients with stage I-III breast cancer,^[@bibr4-1534735418786801],[@bibr6-1534735418786801],[@bibr16-1534735418786801],[@bibr18-1534735418786801],[@bibr24-1534735418786801],[@bibr25-1534735418786801]^ whereas the others did not provide complete details. Participants in 9 RCTs were administered tamoxifen, postoperative radiation, and chemotherapy during the acupuncture intervention^[@bibr3-1534735418786801][@bibr4-1534735418786801]-[@bibr5-1534735418786801],[@bibr7-1534735418786801],[@bibr9-1534735418786801],[@bibr16-1534735418786801],[@bibr23-1534735418786801],[@bibr27-1534735418786801]^; participants in 3 RCTs underwent no postoperative hormone therapy before study onset^[@bibr2-1534735418786801],[@bibr24-1534735418786801],[@bibr25-1534735418786801]^; and those in 2 RCTs received postoperative hormone therapy.^[@bibr17-1534735418786801],[@bibr22-1534735418786801]^ Participants in 2 RCTs^[@bibr6-1534735418786801],[@bibr18-1534735418786801]^ underwent postoperative hormone therapy and chemotherapy during the acupuncture intervention. Program intensities varied, ranging from twice weekly from 20 to 30 minutes each, with treatment durations ranging from 4 to 10 weeks. Acupuncture prescriptions varied in needling protocol, points, and meridian systems; indications for acupuncture mainly focused on hot flashes, fatigue, pain, joint stiffness, mood regulation, and quality of life ([Tables 1](#table1-1534735418786801){ref-type="table"} and [2](#table2-1534735418786801){ref-type="table"}).

Characteristics of the Acupuncture Prescriptions {#section10-1534735418786801}
------------------------------------------------

One RCT^[@bibr4-1534735418786801]^ was based on the National Acupuncture Detoxification Association protocol; 3 RCTs^[@bibr3-1534735418786801],[@bibr16-1534735418786801],[@bibr17-1534735418786801]^ adopted the Revised Standards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA); one^[@bibr19-1534735418786801]^ used TCM textbooks; two^[@bibr18-1534735418786801],[@bibr24-1534735418786801]^ used a manualized protocol of TCM theory; and the others referred to the published literature. The RCTs used full-body or auricular needles varying in size from 0.18 mm × 13 mm to 0.20 mm × 40 mm, and all 17 RCTs used a fixed selection of points.

The meridians and primary points involved 8 locations, including the stomach meridian (ST), *Du mai* (DU), spleen meridian (SP), large intestine meridian (LI), small intestine (SI), liver (LI), lung (LU), and pericardium meridian (P). In 6 RCTs,^[@bibr2-1534735418786801],[@bibr6-1534735418786801],[@bibr16-1534735418786801],[@bibr19-1534735418786801],[@bibr22-1534735418786801],[@bibr25-1534735418786801]^ participants in the control group were administered sham acupuncture. Control group participants underwent progressive relaxation programs,^[@bibr7-1534735418786801],[@bibr27-1534735418786801]^ no treatment, observation at baseline,^[@bibr3-1534735418786801],[@bibr4-1534735418786801]^ normal practice including pharmacological and nonpharmacological options,^[@bibr5-1534735418786801]^ health education,^[@bibr16-1534735418786801]^ and waitlist control,^[@bibr18-1534735418786801],[@bibr22-1534735418786801]^ Manual acupuncture was used in 16 RCTs^[@bibr2-1534735418786801][@bibr3-1534735418786801][@bibr4-1534735418786801][@bibr5-1534735418786801][@bibr6-1534735418786801]-[@bibr7-1534735418786801],[@bibr15-1534735418786801][@bibr16-1534735418786801][@bibr17-1534735418786801]-[@bibr18-1534735418786801],[@bibr21-1534735418786801],[@bibr24-1534735418786801],[@bibr26-1534735418786801],[@bibr27-1534735418786801]^ and electroacupuncture in one^[@bibr25-1534735418786801]^ ([Tables 1](#table1-1534735418786801){ref-type="table"} and [2](#table2-1534735418786801){ref-type="table"}).

Methodological Qualities of the Included Studies {#section11-1534735418786801}
------------------------------------------------

No study fulfilled all methodological criteria. Of the 17 RCTs, 10 reported adequate random sequence generation^[@bibr2-1534735418786801][@bibr3-1534735418786801][@bibr4-1534735418786801][@bibr5-1534735418786801]-[@bibr6-1534735418786801],[@bibr15-1534735418786801],[@bibr16-1534735418786801],[@bibr18-1534735418786801],[@bibr24-1534735418786801]^; in 7, blocks were concealed and sequences were stored in sealed, opaque, numbered envelopes or used another concealed allocation protocol^[@bibr4-1534735418786801],[@bibr7-1534735418786801],[@bibr18-1534735418786801],[@bibr19-1534735418786801],[@bibr24-1534735418786801],[@bibr25-1534735418786801],[@bibr27-1534735418786801]^; 4 adopted blinding of the patients^[@bibr4-1534735418786801],[@bibr16-1534735418786801],[@bibr19-1534735418786801],[@bibr24-1534735418786801]^; 2 adopted blinding of the subjects and/or patients^[@bibr16-1534735418786801],[@bibr17-1534735418786801]^; 2 reported blinding of the subjects and therapists^[@bibr2-1534735418786801],[@bibr25-1534735418786801]^; and 1 reported blinding of the investigators, subjects, statistician, and patients.^[@bibr18-1534735418786801]^

The remaining RCTs did not mention whether other sources of bias were present. Items assessing the Cochrane risk of bias generally demonstrated that the included RCTs demonstrated higher methodological quality involving measures of similarity between the groups at baseline and had \<15% dropouts ([Figure 2](#fig2-1534735418786801){ref-type="fig"}, [Table 3](#table3-1534735418786801){ref-type="table"}).

![Methodological quality of included studies.](10.1177_1534735418786801-fig2){#fig2-1534735418786801}

###### 

Methodological Quality of Included Studies.

![](10.1177_1534735418786801-table3)

  Author/Year                                                              Randomization                                                Allocation Concealment             Blinding                                                     Incomplete Outcome Data   Selective Outcome Reporting   Other Sources of Bias
  ------------------------------------------------------------------------ ------------------------------------------------------------ ---------------------------------- ------------------------------------------------------------ ------------------------- ----------------------------- -----------------------
  Bao et al, 2013,^[@bibr2-1534735418786801]^ United States                Randomized using a computer-generated random numbers table   Mention                            Yes (patients, oncologist, statistician)                     Yes                       Unclear                       Unclear
  Crew et al, 2007,^[@bibr3-1534735418786801]^ United States               Randomized using a computer-generated random numbers table   Mention                            No                                                           Unclear                   Unclear                       Unclear
  Crew et al, 2010,^[@bibr4-1534735418786801]^ United States               Randomized using a computer-generated random numbers table   Using opaque, numbered envelopes   Yes (patients)                                               Unclear                   Unclear                       Unclear
  Deng et al, 2007,^[@bibr15-1534735418786801]^ United States              Randomized using a computer-generated random numbers table   Mention                            Yes (subject, patients)                                      No                        Unclear                       Unclear
  Nedstrand et al, 2005,^[@bibr27-1534735418786801]^ Sweden                Unclear                                                      Using opaque, numbered envelopes   Unclear                                                      Unclear                   Unclear                       Unclear
  Frisk et al, 2008,^[@bibr23-1534735418786801]^ Sweden                    Randomized using random number table                         Unclear                            Unclear                                                      Unclear                   Unclear                       Unclear
  Hervik and Mjåland, 2009,^[@bibr21-1534735418786801]^ Norway             Unclear                                                      Using opaque, numbered envelopes   Yes (patients)                                               Yes                       Unclear                       Unclear
  Hervik and Mjåland, 2014,^[@bibr22-1534735418786801]^ Norway             Mention                                                      No                                 Yes (patients)                                               Yes                       Unclear                       Unclear
  Johnston et al, 2011,^[@bibr5-1534735418786801]^ United States           Randomized using a computer-generated random numbers table   Unclear                            Unclear                                                      No                        Unclear                       Unclear
  Liljegren et al, 2012,^[@bibr6-1534735418786801]^ Sweden                 Randomized using a computer-generated random numbers table   Unclear                            Yes (subject)                                                Yes                       Unclear                       Unclear
  Mao et al, 2014,^[@bibr18-1534735418786801]^ United States (I), Europe   Randomized using a computer-generated random numbers table   Using opaque, numbered envelopes   Yes (study investigators, subject, statistician, patients)   Yes                       Unclear                       Unclear
  Mao et al, 2014,^[@bibr24-1534735418786801]^ United States (II)          Randomized using a computer-generated random numbers table   Using opaque, numbered envelopes   Yes (patients)                                               Yes                       Unclear                       Unclear
  Mao et al, 2015,^[@bibr25-1534735418786801]^ United States               Randomized using a computer-generated random numbers table   Using opaque, numbered envelopes   Yes (investigator, study staff, statistician                 Yes                       Unclear                       Unclear
  Molassiotis et al, 2013,^[@bibr16-1534735418786801]^ United Kingdom      Randomized using random permuted blocks                      Unclear                            Unclear                                                      No                        Unclear                       Unclear
  Nedstrand et al, 2006,^[@bibr7-1534735418786801]^ Sweden                 Unclear                                                      Using opaque, numbered envelopes   Unclear                                                      Yes                       Unclear                       Unclear
  Smith et al, 2013,^[@bibr17-1534735418786801]^ Australia                 Mention                                                      Mention                            Yes (subject, patients)                                      Unclear                   Unclear                       Unclear
  Yao et al, 2016,^[@bibr26-1534735418786801]^ Korea                       Mention                                                      No                                 No                                                           Yes                       Unclear                       Unclear

Outcome Analysis {#section12-1534735418786801}
----------------

Compared with control therapies, the pooled results suggested that acupuncture conferred moderate effects improving stiffness and physical well-being. No significant differences were observed in hot flashes, fatigue, pain, gastrointestinal symptoms, Kupperman index, general well-being, tumor necrosis factor (TNF), and interleukin (IL). No adverse events were reported in any of the included trials ([Table 4](#table4-1534735418786801){ref-type="table"}).

###### 

Effect Sizes of Acupuncture Versus Control Interventions.

![](10.1177_1534735418786801-table4)

  Outcome                     No. of Studies                                                                                                                                                       No. of Patients   Standardized Mean Difference (95% CI)   Heterogeneity *P* Value   *I* ^2^   Test for Overall Effect *P* Value
  --------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------- --------------------------------------- ------------------------- --------- -----------------------------------
  Hot flashes                 6^[@bibr6-1534735418786801],[@bibr7-1534735418786801],[@bibr15-1534735418786801],[@bibr22-1534735418786801],[@bibr25-1534735418786801],[@bibr27-1534735418786801]^   205               −0.15 (−0.37, 0.06)                     .19                       32.6%     .64
  Fatigue                     4^[@bibr5-1534735418786801],[@bibr16-1534735418786801],[@bibr17-1534735418786801],[@bibr24-1534735418786801]^                                                        177               −0.07 (−1.04, 0.90)                     .00                       85.8%     .89
  Pain                        4^[@bibr3-1534735418786801],[@bibr4-1534735418786801],[@bibr7-1534735418786801],[@bibr18-1534735418786801]^                                                          152               −0.01 (−0.70, 0.72)                     .00                       78.8%     .25
  Stiffness                   4^[@bibr3-1534735418786801],[@bibr4-1534735418786801],[@bibr7-1534735418786801],[@bibr26-1534735418786801]^                                                          112               −0.59 (−0.92, −0.26)                    .05                       61.3%     .00
  Gastrointestinal symptoms   5^[@bibr3-1534735418786801],[@bibr4-1534735418786801],[@bibr6-1534735418786801],[@bibr7-1534735418786801],[@bibr16-1534735418786801]^                                282               −0.09 (−0.32, 0.15)                     .72                       0.00%     .92
  Kupperman index             3^[@bibr7-1534735418786801],[@bibr21-1534735418786801],[@bibr23-1534735418786801]^                                                                                   157               −0.36 (−1.08, 0.37)                     .01                       74.7%     .50
  Physical well-being         6^[@bibr3-1534735418786801],[@bibr4-1534735418786801],[@bibr16-1534735418786801],[@bibr17-1534735418786801],[@bibr18-1534735418786801],[@bibr26-1534735418786801]^   240               −0.28 (−0.74, 0.19)                     .00                       68.9%     .42
  Social well-being           3^[@bibr3-1534735418786801],[@bibr4-1534735418786801],[@bibr16-1534735418786801]^                                                                                    176               −0.10 (−0.40, 0.20)                     .95                       0.00%     .51
  Emotional well-being        3^[@bibr3-1534735418786801],[@bibr4-1534735418786801],[@bibr16-1534735418786801]^                                                                                    176               0.02 (−0.50, 0.54)                      .07                       61.4%     .93
  TNF                         2^[@bibr2-1534735418786801],[@bibr3-1534735418786801]^                                                                                                               64                −0.65 (−1.83, 0.54)                     .03                       77.1%     .28
  IL                          2^[@bibr2-1534735418786801],[@bibr3-1534735418786801]^                                                                                                               64                0.15 (−1.36, 1.65)                      .01                       85%       .84

Abbreviations: TNF, tumor necrosis factor; IL, interleukin.

Metaregression and Subgroup Analyses {#section13-1534735418786801}
------------------------------------

Heterogeneity was present in the comparison of studies on fatigue (*I*^2^ = 85.8%), pain (*I*^2^ = 96.1%), gastrointestinal symptoms (*I*^2^ = 81.4), Kupperman index (*I*^2^ = 72.4%), physical well-being (*I*^2^ = 73.5%), emotional well-being (*I*^2^ = 61.4%), and TNF (*I*^2^ = 77.1%) and IL (*I*^2^ = 85%) levels. Meta-regression revealed that the effects of age, clinical stage, intervention, hormone therapy, acupuncture protocol, acupuncture points, control group, indications, and duration of acupuncture practice on physical well-being and gastrointestinal symptoms did not explain the heterogeneity.

Further subgroup analyses were performed according to control groups (sham control, wait-list, relaxation, health education) with regard to hot flashes, pain, fatigue, stiffness, gastrointestinal symptoms, and physical well-being. The analyses indicated that acupuncture had potential advantages in alleviating the symptoms of stiffness; subgroup analysis of stiffness symptom demonstrated that compared with the other control group, the setting of the wait-list control group was more likely to reflect the positive effect of acupuncture ([Figures 3A-3E](#fig3-1534735418786801){ref-type="fig"}, [Table 5](#table5-1534735418786801){ref-type="table"}).

![A forest plot of the effects of the subgroup acupuncture therapies on treatment-related side effects: the width of the horizontal lines represent the 95% CIs of the individual studies, and the squares represent the proportional weight of each study. The diamonds represent the pooled odds ratio and 95% CI. A. Subgroups for hot flashes. B. Subgroups for pain. C. Subgroups for stiffness. D. Subgroups for gastrointestinal symptoms. E. Subgroups for physical well-being.\
Abbreviation: SMD, standardized mean difference.](10.1177_1534735418786801-fig3){#fig3-1534735418786801}

###### 

Effect Sizes of Control Subgroup Analysis.

![](10.1177_1534735418786801-table5)

  Outcome                     No. of Studies                                                                                                                 No. of Patients   OR \[95% CI\]          Heterogeneity *P* Value   *I* ^2^   Test for Overall Effect *P* Value
  --------------------------- ------------------------------------------------------------------------------------------------------------------------------ ----------------- ---------------------- ------------------------- --------- -----------------------------------
  Hot flashes                 4^[@bibr6-1534735418786801],[@bibr15-1534735418786801],[@bibr22-1534735418786801],[@bibr25-1534735418786801]^ (Sham control)   456               −0.15 (−0.40, 0.08)    .06                       59.5%     .19
                              2^[@bibr7-1534735418786801],[@bibr27-1534735418786801]^ (Relaxation)                                                           218               −0.13 (−0.58, 0.32)    .98                       0%        .56
  Pain                        1^[@bibr3-1534735418786801]^ (Sham control)                                                                                    18                0.44 (−0.19, 1.09)     0                         0%        .17
                              2^[@bibr4-1534735418786801],[@bibr18-1534735418786801]^ (Wait-list)                                                            78                −0.28 (−1.82, 1.24)    0                         91.3%     .71
                              1^[@bibr7-1534735418786801]^ (Relaxation)                                                                                      31                0.15 (−0.55, 0.86)     0                                   .67
  Stiffness                   3^[@bibr3-1534735418786801],[@bibr4-1534735418786801],[@bibr7-1534735418786801]^ (Wait-list)                                   101               −0.74 (−1.42, −0.05)   .03                       69.4%     .03
                              1^[@bibr26-1534735418786801]^ (Diosmin)                                                                                        30                −0.36 (−1.08, 0.36)    .06                       58%       .32
  Gastrointestinal symptoms   2^[@bibr3-1534735418786801],[@bibr4-1534735418786801]^ (Wait-list)                                                             56                −0.30 (−0.76, 0.15)    .36                       0%        .83
                              1^[@bibr6-1534735418786801]^ (Sham control)                                                                                    74                −0.04 (−0.43, 0.34)    0                         0%        .90
                              1^[@bibr16-1534735418786801]^ (Health education)                                                                               105               −0.04 (−0.74, 0.66)    0                         0%        .84
                              1^[@bibr7-1534735418786801]^ (Relaxation)                                                                                      31                0.04 (−0.41, 0.50)     0                         0%        .46
  Fatigue                     2^[@bibr16-1534735418786801],[@bibr17-1534735418786801]^ (Wait-list)                                                           56                0.17 (−2.13, 2.49)     0                         90.9%     .88
                              2^[@bibr5-1534735418786801],[@bibr24-1534735418786801]^ (Health education)                                                     121               −0.35 (−1.48, 0.77)    .02                       79.1%     .53
  Physical well-being         3^[@bibr3-1534735418786801],[@bibr4-1534735418786801],[@bibr18-1534735418786801]^ (Wait-list control)                          96                −0.29 (−1.30, 0.70)    0                         86.1%     .56
                              2^[@bibr3-1534735418786801],[@bibr4-1534735418786801]^ (Health education)                                                      145               −0.09 (−0.45, 0.26)    .96                       0%        .59
                              1^[@bibr26-1534735418786801]^ (Diosmin)                                                                                        30                −0.59 (−1.33, 0.13)    0                         0%        .10

Abbreviation: OR, odds ratio.

Discussion {#section14-1534735418786801}
==========

Postoperative breast cancer patients experience treatment-related side effects (fatigue, pain, stiffness, somatic dysfunction, emotional stress, and gastrointestinal symptoms) that occur together with hormone therapy--related cardiovascular events (hot flashes) and anxiety in varying degrees. Acupuncture therapy was associated with reduced risk of clinical outcomes versus placebo, based on 17 RCTs with 4 weeks to 6 months of follow-up (summarized in [Table 3](#table3-1534735418786801){ref-type="table"}). Although the RCTs evaluated diverse populations, the findings were generally consistent with regard to improved stiffness of the affected limb(s).

Acupuncture protocols of the included studies varied and are a possible source of heterogeneity. These findings regarding benefits associated with acupuncture therapy were generally consistent with findings from recent RCTs that demonstrate that acupuncture has been used for postoperative treatment-related side effects and hormone therapy--related psychosomatic event management in patients who are breast cancer survivors, despite the variability in inclusion criteria, use of individual-patient data, and analytic methods.^[@bibr5-1534735418786801],[@bibr21-1534735418786801],[@bibr22-1534735418786801],[@bibr25-1534735418786801],[@bibr28-1534735418786801]^

In contrast with the recent RCTs, the current level of evidence from a series of meta-analyses is insufficient to suggest that acupuncture is an effective treatment for postoperative treatment-related side effects and hormone therapy--related psychosomatic events in patients with breast cancer.^[@bibr15-1534735418786801],[@bibr29-1534735418786801][@bibr30-1534735418786801][@bibr31-1534735418786801]-[@bibr32-1534735418786801]^

Physical Parameters {#section15-1534735418786801}
-------------------

The present systematic review found evidence that acupuncture could potentially relieve stiffness in the affected limb(s), whereas statistically significant differences were not found for other hormone therapy--related side effects, including hot flashes, fatigue, pain, the Kupperman index, physical well-being or gastrointestinal symptoms. Further subgroup analysis of pain, hot flashes, gastrointestinal symptoms, and physical well-being also did not show sensitivity to control settings.

The majority of acupuncture treatments administered to reduce hormone therapy--related side effects were scarcely better than a placebo.^[@bibr33-1534735418786801]^ Previous studies have reported that acupuncture failed to manage somatic symptoms of adjuvant hormonal therapy such as hot flashes^[@bibr23-1534735418786801],[@bibr24-1534735418786801],[@bibr34-1534735418786801]^ and fatigue.^[@bibr7-1534735418786801],[@bibr35-1534735418786801],[@bibr36-1534735418786801]^ However, Nedstrand et al^[@bibr7-1534735418786801]^ reached the opposite conclusion, and some RCTs reported AI-related joint symptoms improvement, reduced pain,^[@bibr2-1534735418786801],[@bibr3-1534735418786801]^and improved Kupperman index.^[@bibr12-1534735418786801],[@bibr27-1534735418786801]^ To date, the effect size has not been quantified, and the available evidence conveys mixed and inconclusive results. Clinical practice guidelines for CAM in breast cancer report that RCTs have shown no clear benefit of efficacy and are neither strongly positive nor negative.^[@bibr37-1534735418786801]^

The question remains as to whether an acupuncture intervention is truly inert or if it induces physiological effects. The acupuncture points used in these RCTs were designed to reduce hormone therapy--related side effects in breast cancer patients; however, almost all acupuncture points overlap with those used to improve various other somatic symptoms; meanwhile, control group settings and individual differences in patients may partially explain the failure of the acupuncture interventions to elicit effects.

It is noteworthy that risk of bias was relatively low, and we are cautiously optimistic about the statistically significant results regarding stiffness. This analysis provides basic data regarding the power and effect size for treatment of stiffness that are needed to design an RCT, which is difficult to determine thoughtfully by standardized mean difference.

Pathological Outcomes {#section16-1534735418786801}
---------------------

AI-associated musculoskeletal pain occurs in approximately 5% to 36% of breast cancer survivors undergoing treatment and can lead to treatment discontinuation.^[@bibr38-1534735418786801]^ In postmenopausal breast cancer survivors, estrogen deprivation increases pain as well as impairs descending pain inhibitory pathways. This may be a risk factor for women undergoing AI therapy experiencing musculoskeletal disorders, including joint pain and stiffness.^[@bibr39-1534735418786801]^

Findings from increasing evidence-based basic and clinical research suggests that pain is sensitive to acupuncture procedures. The mechanism of acupuncture was reinterpreted in an evidence-based approach in the framework of systems biology. The analgesic effect of acupuncture on chronic neuropathic pain has been shown to be mediated by P2 X3 receptors of purinergic signaling and is identified with specific neurons that are activated via stimulation of ATP flux in the brains of rat animal models.^[@bibr40-1534735418786801],[@bibr41-1534735418786801]^ The pain mechanism of acupuncture in humans needs to be confirmed in a clinical evidence-based framework of acupuncture-induced analgesia.

In effect, a clinical study based on an RCT can be considered a reverse targeting and screening approach, designed to uncover multiple acupuncture target pathways related to cancer. In contrast to Western medicine, acupuncture puts forth a very different definition of a disease and encompasses all of the symptoms a patient presents with. Because of the highly interconnected nature of the breast cancer interactome, acupuncture is dynamic with changing boundaries, overlapping symptoms, and a multiscale nature, which makes it difficult to understand at a biological and mechanistic level. Interestingly, Henry et al^[@bibr42-1534735418786801]^ reported that the average pain threshold at the 3-month time point was significantly lower in patients who discontinued AI therapy within 6 months. This suggests that, at least in some breast cancer patients, there may be an association between increased sensitivity to pain and impaired pain modulation before initiation of treatment; this may also be an explanation of why the pain symptoms do not show relief in this study.

Results of the present study showed that there were no significant biomarker changes in the levels of IL, in agreement with previous studies.^[@bibr43-1534735418786801]^ Mediators of inflammation are a family of signal transducers and activators of cytokine transcription factors that play various roles in cellular processes, including immune response, apoptosis, and oncogenesis.^[@bibr44-1534735418786801]^ However, high levels of cytokines can induce more cell migration, which is dependent on both signal transducers and activators of transcription and NF-κB (nuclear factor κ-light-chain-enhancer of activated B cells), suggesting that in vivo, local inflammation caused by the growth of a tumor may result in high levels of inflammatory cytokines such as IL-6 and TNF-α in the tumor microenvironment, which would then lead to tumor cell migration and metastasis.^[@bibr45-1534735418786801][@bibr46-1534735418786801]-[@bibr47-1534735418786801]^

Our findings suggest that acupuncture had no impact on inflammatory markers. A longer-term intervention with acupuncture may be necessary to observe some of its potential benefits. Given the effect sizes for this inflammation marker, the results should be interpreted with caution because this analysis did not have sufficient statistical power to evaluate the effects of either acupuncture or IL levels in the total sample, also considering that there were heterogeneous levels of IL at enrollment. Restrictions imposed by the small sample size limit the ability to interpret these results in a biological context. This is also a positive reminder that present consensus is gradually moving in this bioinformatics and bionetwork model through a systems biology approach to identify the relevance between cytokines/mediators of inflammation and acupuncture.

External and Internal Validity {#section17-1534735418786801}
------------------------------

Interventions were usually well described but of limited applicability because they often used protocols requiring the acupuncturist to select points based on past experience. No RCT mentioned how the points and needling combine. Point selection varied and focused on proving the effects of acupuncture. No RCT in our meta-analysis used an individually tailored prescription of points; only one reported a protocol in accordance with the STRICTA.^[@bibr15-1534735418786801]^

Moreover, when using sham acupuncture (no needle insertion or very shallow insertion) as a placebo control, it is worth considering whether it is a suitable placebo intervention because of the possibility that sham acupuncture has an active effect related to peripheral sensory stimulation, making it difficult to fix specific points on the body to eliminate the placebo effect. Unfortunately, acupuncture prescriptions are still unstandardized.

Patients were, therefore, not treated optimally according to TCM principles. Future studies should investigate point selection in accordance with TCM theory as opposed to a set point prescription. Moreover, designs should address blinding the therapist to the treatment because double-blinding is a significant problem in acupuncture trials. In one RCT, patients were given antidepressants as supplements to help them cope with menopausal symptoms (eg, selective serotonin reuptake inhibitor or a serotonin norepinephrine reuptake inhibitor).^[@bibr15-1534735418786801]^

Potential Biases in the Review Process {#section18-1534735418786801}
--------------------------------------

The small number of RCTs may have caused the lack of statistical significance. Although the results were adjusted for a wide range of covariates, the possibility of heterogeneity still exists. Residual confounding factors, including the characteristics of the acupuncture prescription, age at diagnosis, disease stage and severity, frequency, duration of the intervention for treatment-related side effects, indications for acupuncture, hormone prescription, lifestyle factors, and self-reported quality of life could not be completely excluded, and the findings thus could not result in a reasonable recommendation.

All the included studies analyzed the settings of the control group, which indicated the significance of the control group in each study. In one RCT, control patients were given diosmin (900 mg tablets, orally 3 times daily) to help them cope with symptoms of lymphedema,^[@bibr26-1534735418786801]^ which led to a bias in determining a specific therapeutic effect of acupuncture because of inadequate control for nonspecific effects among breast cancer patients. Subgroup analysis revealed that effects on acupuncture outcomes are sensitive to the type of control group. The estimation of the effect size for control groups in the RCTs reinforced the lesson that when there is an imbalance in the baseline of control participants, results may be unstable, masked, or amplified. Each RCT used a different study design and implemented control groups differently. Choice of the control group was far more important than acupuncture protocols as a determinant of outcome in some ways: this deficiency was itself partly a result of the design of control groups.

We did not find statistically significant differences in hormone therapy--related outcome indicators between the control subgroups (sham, wait-list, relaxation, drug group, and health education) and real acupuncture groups. Subgroup analysis was not sensitive to the influence of the outcome indicators. Despite this, the nonsignificant findings may also have occurred because sham/minimal acupuncture is not inert, with real acupuncture and sham/minimal acupuncture shown to induce a significant physiological response in a recent study.^[@bibr48-1534735418786801]^

Any type of physiological stimulus, including tactile, is capable of stimulating multimodal receptors of C-fiber primary afferents that can modulate the limbic system and, thus, reduce the affective components of pain.^[@bibr49-1534735418786801]^ RCTs that used sham acupuncture controls suggest that sham acupuncture may be as effective as real acupuncture; based on the small sample size, evidence-based well-designed trials are still needed to confirm these findings.

In conclusion, hormone therapy--related side effects remain a major component of the symptom burden in breast cancer patients, and many oncologists discontinue aromatase-inhibitor therapies, so that their patients will experience reductions in symptoms and regain quality of life. Borderline evidence suggests that acupuncture may be safe and effective for managing joint stiffness; however, the small sample sizes and risk of bias limit the interpretation of the results. Our ﬁndings add to the small but growing body of literature suggesting that acupuncture may not have clinical beneﬁts in reducing common hormone therapy--related side effects with respect to psychosomatic symptoms and quality of life.

**Declaration of Conflicting Interests:** The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding:** The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: We are indebted to the following education and research institutions for financial support. (1) Key Project of the 2017 year, Vocational Technical Education Branch of Higher Education Research Academy of China: Research on the Path of the Application of Evidence-based Medical Education and Knowledge Transformation in Higher Medical Vocational Education (Grant No: GZYZD2017012). (2) Key Project of the 2017 year, Tianjin Higher Vocational and Technical Education Research Institute: the International Standard and Path Study on the Advanced Training of JBI Health Care Model for Higher Medical Vocational Education (Grant No: 106). (3) Lanzhou Municipal Science and Technology Bureau of Gansu province of China of Science and Technology Project (medical and health special): Applicability Evaluation of Systematic Review of Breast Cancer Treated with Non Drug Complementary Alternative Medicine (Grant No: 2016-2-68).
